A systematic review of therapeutic options for lymphocytic esophagitis
Diseases of the Esophagus · 2025
DOI: 10.1093/dote/doaf112 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Diseases of the Esophagus, 2025. Verfasst von Bachviet Nguyen und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of British Columbia, 13750, 96 Ave. Critical Care Tower, 3rd Floor, Surrey, British Columbia, V3V 1Z2, Canada. Hauptthemen laut MEDLINE: Proton Pump Inhibitors, Esophagitis. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Lymphocytic esophagitis (LyE) is a novel rare esophageal disorder characterized by intraepithelial lymphocytic infiltration of the esophagus in a peripapillary distribution, without the involvement of granulocytes. The optimal treatment strategy for this condition remains uncertain. We aimed to synthesize the current evidence for the treatment of lymphocytic esophagitis.
Methods
We performed a systematic review according to PRISMA guidelines, searching MEDLINE, Embase, and Google Scholar. Studies with non-primary data or insufficient treatment data were excluded. Descriptive statistics were performed on patient demographics and treatment outcomes.
Results
Thirty nine articles from 2012–2024 were included (154 patients total). Proton pump inhibitors (PPIs) were the most common initial therapy for LyE (n = 65), followed by topical steroids (n = 23). A greater proportion of patients experienced a symptomatic, endoscopic, and histologic response from the initial use of topical steroids as monotherapy or part of combination therapy (with PPIs) compared to PPIs alone. Symptomatic recurrence was more common after initial use of topical steroids compared to PPIs. Balloon dilation was effective in relieving symptomatic esophageal dysphagia. Other therapies included biologics, endoscopic botulinum injections, sucralfate, and tacrolimus. The average follow-up duration was 8.98 months.
Conclusions
For patients with LyE, topical steroids seem to provide greater symptomatic and histologic benefit compared to PPIs, although recurrence is more common. For patients not already on acid suppression therapy, PPIs may still be a reasonable first-line option, especially when prioritizing safety. Further prospective studies are needed to formally assess the comparative safety and efficacy of the various treatment modalities, including novel immunosuppressive therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, University of British Columbia, 13750, 96 Ave. Critical Care Tower, 3rd Floor, Surrey, British Columbia, V3V 1Z2, Canada.
- Department of Statistics, University of British Columbia, 3182 Earth Sciences Building, 2207 Main Mall, Vancouver V6T 1Z4, Canada.
- Division of Gastroenterology, University of British Columbia Okanagan, 564 Leon Avenue, Kelowna, V1Y 6J6, Canada.
ORCID-Profile: Bachviet Nguyen, Fahd Jowhari
Zitieren
APA
Nguyen, B., Cheng, C. F., & Jowhari, F. (2025). A systematic review of therapeutic options for lymphocytic esophagitis. Diseases of the Esophagus. https://doi.org/10.1093/dote/doaf112
Vancouver
Nguyen B, Cheng CF, Jowhari F. A systematic review of therapeutic options for lymphocytic esophagitis. Diseases of the Esophagus. 2025. doi:10.1093/dote/doaf112
BibTeX
@article{Nguyen2025,
author = {Nguyen, Bachviet and Cheng, Chun Fang and Jowhari, Fahd},
title = {A systematic review of therapeutic options for lymphocytic esophagitis},
journal = {Diseases of the Esophagus},
year = {2025},
doi = {10.1093/dote/doaf112}
}
EUVIMED